Results 191 to 200 of about 37,220 (200)

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Cell, 2010
Steven R Whittaker, Nathalie Dhomen, Richard Marais   +2 more
exaly  

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

New England Journal of Medicine, 2010
Keith T Flaherty, Igor Puzanov, Kevin B Kim   +2 more
exaly  

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

Cancer Cell, 2015
Eishu Hirata, Amaya Viros, Michiyuki Matsuda   +2 more
exaly  

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

Cancer Cell, 2013
Rizwan Haq, Glenn C Rowe, Abhinav Nellore   +2 more
exaly  

Vemurafenib: the first drug approved for BRAF-mutant cancer

Nature Reviews Drug Discovery, 2012
exaly  

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Lancet, The, 2015
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas   +2 more
exaly  

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Nature Reviews Clinical Oncology
Ziyu Chen, David B Solit
exaly  

BRAF-/MEK-Inhibition wirksam bei BRAF-V600E-Mutation

Im Fokus Onkologie
openaire   +1 more source

Targetable Mutations in BRAF V600E–Negative Hairy-Cell Leukemia

New England Journal of Medicine
Santi, Alessia, Venanzi, Alessandra, Pucciarini, Alessandra, Schiavoni, Gianluca, Naccari, Marta, Albi, Elisa, De Paoli, Lorenzo, Intermesoli, Tamara, Lazzi, Stefano, Conte, Esmeralda, Mancini, Alessandro, Falini, Brunangelo, Gozzetti, Alessandro, D'Elia, Gianna M, Genua, Angelo, Tiacci, Enrico   +15 more
openaire   +3 more sources

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma

Cancer Cell
exaly